| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-05-20 | Ablynx (Belgium) | € 100 million | private placement | Cancer - Oncology - Immunological diseases - Respiratory diseases | Private placement | |
| 2015-05-20 | Companion Medical (USA - CA) | series B financing round | Eli Lilly (USA - IN) Diamyd Medical (Sweden) | Metabolic diseases | Series B financing round | |
| 2015-05-20 | RegenXBio (USA - MD) | $70.5 million | series D financing round | Venrock (USA - CA) Brookside Capital (USA - MA) Vivo Capital (USA - CA) Deerfield Management (USA - NY) Fidelity BioSciences (USA - MA) a fund managed by Janus Capital Management (USA - CO); Jennison Associates (USA - NY) on behalf of clients; Perceptive Advisors (USA - NY) QVT Financial (USA - NY) Tourbillon Global Ventures; Sectoral Asset Management (Canada) Cormorant Asset Management (USA - MA) Foresite Capital Management (USA - CA) RTW Investments (USA - NY) and two undisclosed blue-chip investment funds | Rare diseases - Genetic diseases | Series D financing round |
| 2015-05-20 | Auris Medical (Switzerland) | $22.9 million | private placement | Otorhinolaryngology | Private placement | |
| 2015-05-19 | Galapagos (Belgium) | € 279 million | IPO | IPO | ||
| 2015-05-19 | Anagenesis Biotechnologies (France) | undisclosed | financing round | Cap Innov’Est (France) | Neuromuscular diseases - Regenerative medicine | Financing round |
| 2015-05-18 | Abcodia (UK) | £5.25 million | financing round | Cambridge Innovation Capital (CIC) (UK) Scottish Equity Partners (SEP) (UK) Albion Ventures (UK) UCL Business (UK) | Diagnostic - Cancer - Oncology | Financing round |
| 2015-05-18 | Oryzon Genomics (Spain) | $270,000 | grant | The Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) | Neurodegenerative diseases | Grant |
| 2015-05-15 | Cortendo (Sweden) | $33.2 million | private placement | TVM Capital (Germany) Longwood Capital (USA - China) Granite Point Capital (USA - MA) RA Capital (USA - MA) New Enterprise Associates (USA - MD) Broadfin Capital (USA - NY) HealthCap (Sweden) | Rare diseases - Hormonal diseases - Endocrine diseases | Private placement |
| 2015-05-15 | Circassia Pharmaceuticals (UK) | £275 million (€ 380 million) | private placement | Allergic diseases - Inflammatory diseases - Respiratory diseases | Private placement | |
| 2015-05-14 | Denali Therapeutics (USA - CA) | $ 217 million | financing round | Fidelity Biosciences (USA - MA), ARCH Venture Partners (USA - IL), Flagship Ventures (USA - MA), Alaska Permanent Fund (USA - AK), sovereign wealth funds, public mutual funds and private family offices | Neurodegenerative diseases | Financing round |
| 2015-05-13 | Cell Cure Neurosciences (Israel) | 6.24 million shekels (approximately $1.61 million ) | grant | Office of the Chief Scientist (OCS -Israel) | Grant | |
| 2015-05-12 | Juventas Therapeutics (USA - OH) | $13.5 million | Green Cross Holdings (South Korea) POSCO Capital (South Korea) other new and existing investors | Cardiovascular diseases | Series B financing round | |
| 2015-05-12 | Ixico (UK) | £1 million | grant | Innovate UK (UK) | CNS diseases | Grant |
| 2015-05-12 | Affimed (Germany) | $37.1 million | private placement | Cancer - Oncology | Private placement | |
| 2015-05-12 | Antabio (France) | €4 million | grant | Wellcome Trust (UK) | Infectious diseases - Rare diseases | Grant |
| 2015-05-12 | Bavarian Nordic (Denmark) | € 50 million | loan | European Investment Bank (EIB) (EU) | Infectious diseases | Loan |
| 2015-05-11 | Adaptimmune (UK) | $175.7 million | IPO | Cancer - Oncology | IPO | |
| 2015-05-08 | Neurovive Pharmaceutical (Sweden) | SEK 70 million (€ 7.5 million) | private placement | Capital increase | ||
| 2015-05-06 | Atyr Pharma (USA - CA) | IPO | Cancer - Oncology - Rare diseases - Genetic diseases | IPO |
